MiNK Therapeutics Inc. Common Stock Earnings Recaps
Q1 2026
May 16, 2026
Shares rose modestly by 2.0% following the earnings update as the company highlighted ongoing clinical progress and new trial initiations, though the market showed restraint, indicating results and developments were broadly in line with expectations without clear breakthroughs.
Key takeaways
- Presented Phase II clinical data for refractory gastric cancer showing prolonged median overall survival beyond 23 months in a heavily pretreated, checkpoint-refractory patient population.
- Introduced a randomized Phase II trial for severe acute lung injury and ARDS, designed with a seamless Phase II/III pathway to accelerate potential registrational development.
- Highlighted translational findings demonstrating the platform’s mechanistic immune modulation versatility across distinct disease areas including cancer and severe lung injury.
- Announced a strategic collaboration to advance targeted TCR engineered iNKT therapies for pediatric cancers, aiming to leverage off-the-shelf cell therapy advantages in a high-need area.
- Safety profile across approximately 100 patients treated remains favorable with no new red flags noted, supporting continued clinical development.
Q3 2025
Nov 14, 2025
MiNK Therapeutics achieved significant clinical milestones in Q3 2025, demonstrating promising survival outcomes for patients with relapsed or refractory cancers through its investigational AGENT-797 therapy, while strengthening collaborations and enhancing its operational independence.
Key takeaways
- AGENT-797 therapy demonstrated a remarkable median overall survival of approximately 23 months in patients treated for resistant solid tumors, far exceeding expectations for this patient cohort.
- The therapy exhibited a strong safety profile, with no major toxicities observed, underscoring its potential as a viable treatment option in challenging cancer cases.
- MiNK has established strategic partnerships with the University of Wisconsin and received significant funding support for advancing its iNKT cell therapy platform, aimed at improving outcomes post-stem cell transplantation.
- The company's leadership was strengthened with the appointment of Dr. John Holcomb to the Board, enhancing its strategic vision in clinical development and partnerships.
- MiNK Therapeutics is positioned as a leader in the allogeneic iNKT cell space, bolstered by its scientific advancements and disciplined capital utilization.